Click here to view in chapter format
Agenda
| 00:00:00 | Opening Remarks Dr. Lawrence A. Leiter |
| Updates in Glycemic Control | |
| 00:01:05 | National and international guideline updates Dr. Amir K. Hanna |
| 00:21:32 | Individualizing therapy in 2016-2017 Dr. Ronald M. Goldenberg |
| 00:43:42 | The dance of two devils: Hypoglycemia and cardiovascular risk Dr. Subodh Verma |
| Cardiovascular Safety Trials in Type 2 Diabetes | |
| 01:04:39 | Completed and ongoing trials with DPP-4 inhibitors Dr. Lawrence A. Leiter |
| 01:26:02 | Completed and ongoing trials with SGLT2 inhibitors Dr. Bernard Zinman |
| 02:07:26 | Explaining the benefits of SGLT2 inhibitors and GLP-1 receptor agonists Dr. Subodh Verma |
| 02:33:58 | Plenary Lecture #1: Interleukins and Diabetes: Why should I care? Dr. Paul M. Ridker |
| 03:11:45 | Plenary Lecture #2: Keeping up with a moving BP target Dr. Philip A. McFarlane |
| New Clinical Trial Evidence for Special Groups | |
| 03:36:06 | The diabetic kidney Dr. David Z. I. Cherney |
| 03:58:09 | Obesity treatment: does it move the dial with respect to cardiovascular risk? Dr. Marie-France Langlois |
| 04:19:22 | Front and centre with diabetic dyslipidemia Dr. Robert A. Hegele |
Video Information
- Credit:No Credit Available
- Post Date:December 15, 2016
- Expiry Date:N/A
